Djordje Atanackovic

Associate Professor of Internal Medicine and
Adjunct Associate Professor of Microbiology & Immunology

Djordje Atanackovic

M.D. Free University Berlin

Research

References

djordje.atanackovic@hci.utah.edu

Djordje Atanackovic's Lab Page

Djordje Atanackovic's PubMed Literature Search

 

 

 

Molecular Biology Program

Cancer Immunotherapy, Tumor Immunology, Adoptive Cell Therapy, Chimeric Antigen Receptor (CAR) T Cells, T Cell Receptor (TCR)-transduced T Cells, T Cells, Monoclonal Antibodies

Research

  • Diagnosis and Treatment of Patients with Multiple Myeloma Including High-dose Chemotherapy Plus Autologous Stem Cell Transplantation
  • Identification of Targets for Immunotherapies in Hematologic Malignancies and Solid Tumors
  • Development and Standardization of New Techniques for the Monitoring of Anti-Tumor Immune Responses
  • Analysis of Spontaneously Occurring Antibody and T Cell Responses Against Tumor Antigens in Patients with Various Malignancies
  • Development of Monoclonal Antibodies against Tumor-associated Antigens
  • Development of T Cell-Based Adoptive Immunotherapies for Different Tumor Types (CAR T cells, TCR-transduced T cells)

References

  1. Templin, J., Atanackovic, D., Luetkens, T. (2017) Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. Oncotarget 8: 49253-49263
  2. Zhao, P., Atanackovic, D., Dong, S., Yagita, H., He, X., Chen, M. (2017) An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle. Molecular Pharmacology 14: 1494-1500
  3. Lajmi, N., Luetkens, T., Yousef, S., Templin, J., Cao, Y., Hildebrandt, Y., Bartels, K., Kröger, N., Atanackovic, D. (2015) Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma. British Journal of Haematology 17: 752-762
  4. Yousef, S., Kovacsovics-Bankowski, M., Salama, M.E., Bhardwaj, N., Steinbach, M., Langemo, A., Kovacsovics, T., Marvin, J., Binder, M., Panse, J., Kröger, N., Luetkens, T., Atanackovic, D. (2015) CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Human Vaccines & Immunotherapeutics 11: 1606-1611
  5. Yousef, S., Marvin, J., Steinbach, M., Langemo, A., Kovacsovics, T., Binder, M., Kröger, N., Luetkens, T., Atanackovic, D. (2015) Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. Blood Cancer Journal 5: e285
  6. Luetkens, T., Kobold, S., Cao, Y., Ristic, M., Schilling, G., Tams, S., Bartels, B.M., Templin, J., Bartels, K., Hildebrandt, Y., Yousef, S., Marx, A., Haag, F., Bokemeyer, C., Kröger, N., Atanackovic, D. (2014) Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunology Immunotherapy 63: 1151-1162
  7. Reinhard, H., Yousef, S., Luetkens, T., Fehse, B., Berdien, B., Kröger, N., Atanackovic, D. (2014) Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer Journal 4: e212
  8. Atanackovic, D., Reinhard, H., Meyer, S., Spöck, S., Grob, T., Luetkens, T., Yousef, S., Cao, Y., Hildebrandt, Y., Templin, J., Bartels, K., Lajmi, N., Stoiber, H., Kröger, N., Atz, J., Seimetz, D., Izbicki, J.R., Bokemeyer, C. (2013) The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines & Immunotherapeutics 9: 2533-2542
  9. Atanackovic, D., Hildebrandt, Y., Templin, J., Cao, Y., Keller, C., Panse, J., Meyer, S., Reinhard, H., Bartels, K., Lajmi, N., Sezer, O., Zander, A.R., Marx, A.H., Uhlig, R., Zustin, J., Bokemeyer, C., Kröger, N. (2012) Role of interleukin 16 in multiple myeloma.Journal of the National Cancer Institute 104: 1005-1020
  10. Kobold, S., Tams, S., Luetkens, T., Cao, Y., Sezer, O., Bartels, B.M., Reinhard, H., Templin, J., Bartels, K., Hildebrandt, Y., Lajmi, N., Marx, A., Haag, F., Bokemeyer, C., Kröger, N., Atanackovic, D. (2011) Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clinical and Developmental Immunology 2011: 302145
  11. Atanackovic, D., Panse, J., Hildebrandt, Y., Jadczak, A., Kobold, S., Cao, Y., Templin, J., Meyer, S., Reinhard, H., Bartels, K., Lajmi, N., Zander, A.R., Marx, A.H., Luetkens, T., Bokemeyer, C., Kroger, N. (2011) Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 96: 1512-1520
  12. Cao Y., Luetkens, T., Kobold, S., Hildebrandt, Y., Gordic, M., Lajmi, N., Meyer, S., Bartels, K., Zander, A.R., Bokemeyer, C., Kröger, N., Atanackovic, D. (2010) The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Experimental Hematology38: 860-867
  13. Cao, Y., Gordic, M., Kobold, S., Lajmi, N., Meyer, S., Bartels, K., Hildebrandt, Y., Luetkens, T., Ihloff, A.S., Kröger, N., Bokemeyer, C., Atanackovic, D. (2010) An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.Journal of Immunological Methods358: 56-65
  14. Atanackovic, D., Hildebrandt, Y., Jadczak, A., Cao, Y., Luetkens, T., Meyer, S., Kobold, S., Bartels, K., Pabst, C., Lajmi, N., Gordic, M., Stahl, T., Zander, A.R., Bokemeyer, C., Kröger; N. (2010) Cancer-testis antgens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 95: 785-793
  15. Cao, Y., Gnjatic, S., Reichelt, U., Yekebas, E.F., Nölkers, C., Marx, A., Erbersdobler, A., Nishikawa, H., Hildebrandt, Y., Bartels, K., Horn, C., Stahl, T., Luetkens, T., Ritter, G., Friedrichs, K., Leuwer, R., Hegewisch-Becker, S., Izbicki, J.R., Bokemeyer, C., Old, L.J., Atanackovic, D. (2010) NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. International Journal of Cancer 127: 381-393
  16. Atanackovic, D., Luetkens, T., Hildebrandt, Y., Arfsten, J., Bartels, K., Horn, C., Stahl, T., Cao, Y., Zander, A.R., Bokemeyer, C., Kroger, N. (2009) Longitudinal analysis and prognostic impact of cancer-testis antigen expression in multiple myeloma. Clinical Cancer Research 15: 1343-1352
  17. Panse, J., Friedrichs, K., Marx, A., Hildebrandt, Y., Luetkens, T., Bartels, K., Horn, C., Stahl, T., Cao, Y., Milde-Langosch, K., Niendorf, A., Kröger, N., Wenzel, S., Leuwer, R., Bokemeyer, C., Hegewisch-Becker, S., Atanackovic, D. (2008) Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. British Journal of Cancer99: 930-938
  18. Atanackovic, D., Cao, Y., Luetkens, T., Panse, J., Faltz, C., Arfsten, J., Bartels, K., Wolschke, C., Eiermann, T., Zander, A.R., Fehse, B., Bokemeyer, C., Kroger, N. (2008) CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 93: 419-426
  19. Atanackovic, D., Altorki, N.K., Cao, Y., Ritter, E., Ferrara, C., Ritter, G., Hoffman, E.W., Bokemeyer, C., Old, L.J., Gnjatic, S. (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proceedings of the National Academy of Sciences USA 105: 1650–1655
  20. Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G., Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D.K., Zander, A.R., Old, L.J., Bokemeyer, C., Kröger, N. (2007) Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109: 1103-1112
  21. Atanackovic, D., Block, A., de Weerth, A., Faltz, C., Hossfeld, D.K., Hegewisch-Becker, S. (2004) Characterization of effusion-infiltrating T cells: benign versus malignant effusions. Clinical Cancer Research 10: 2600-2608
  22. Atanackovic, D., Altorki, N.K., Stockert, E., Williamson, B., Jungbluth, A., Ritter, E., Santiago, D., Ferrara, C.A., Matsuo, M., Selvakumar, A., Dupont, B., Chen, Y.T., Hoffman, E.W., Ritter, G., Old, L.J., Gnjatic, S. (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. Journal of Immunology 172: 3289-3296

 Reviews

  1. Atanackovic, D., Luetkens, T. (2018) Biomarkers for checkpoint inhibition in hematologic malignancies. Seminars in Cancer Biology [Epub ahead of print]
  2. Radhakrishnan, S.V., Bhardwaj, N., Luetkens, T., Atanackovic, D. (2017) Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Oncoimmunology 6: e1308618
  3. Atanackovic, D., Steinbach, M., Radhakrishnan, S.V., Luetkens, T. (2016) Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology 5: 1217374
Last Updated: 12/6/18